AU2018295118B2 - Multi-specific antibodies and methods of making and using thereof - Google Patents

Multi-specific antibodies and methods of making and using thereof Download PDF

Info

Publication number
AU2018295118B2
AU2018295118B2 AU2018295118A AU2018295118A AU2018295118B2 AU 2018295118 B2 AU2018295118 B2 AU 2018295118B2 AU 2018295118 A AU2018295118 A AU 2018295118A AU 2018295118 A AU2018295118 A AU 2018295118A AU 2018295118 B2 AU2018295118 B2 AU 2018295118B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018295118A
Other languages
English (en)
Other versions
AU2018295118A1 (en
Inventor
Bill Brady
Katrina BYKOVA
Zeren Gao
David JELLYMAN
Brian Kovacevich
Yu Liang
Ole Olsen
Blair RENSHAW
Anne-Marie Rousseau
Dong Xia
Yi Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of AU2018295118A1 publication Critical patent/AU2018295118A1/en
Assigned to SYSTIMMUNE, INC., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: SICHUAN BAILI PHARMACEUTICAL CO. LTD., SYSTIMMUNE, INC.
Assigned to SYSTIMMUNE, INC. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., SYSTIMMUNE, INC.
Application granted granted Critical
Publication of AU2018295118B2 publication Critical patent/AU2018295118B2/en
Priority to AU2025204860A priority Critical patent/AU2025204860A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018295118A 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof Active AU2018295118B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204860A AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204860A Division AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Publications (2)

Publication Number Publication Date
AU2018295118A1 AU2018295118A1 (en) 2020-02-06
AU2018295118B2 true AU2018295118B2 (en) 2025-04-17

Family

ID=64742644

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018295118A Active AU2018295118B2 (en) 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof
AU2025204860A Pending AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204860A Pending AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Country Status (10)

Country Link
US (1) US11787863B2 (https=)
EP (1) EP3645049A4 (https=)
JP (1) JP7399852B2 (https=)
KR (2) KR102763369B1 (https=)
CN (4) CN110831973B (https=)
AU (2) AU2018295118B2 (https=)
CA (1) CA3068045A1 (https=)
IL (2) IL313468A (https=)
SG (1) SG11201912864SA (https=)
WO (1) WO2019005639A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
US20250346681A1 (en) * 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010136172A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2015013671A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015150447A1 (en) * 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Multispecific antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002311919B8 (en) * 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2611814A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN104072613A (zh) * 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3060579A1 (en) * 2013-10-25 2016-08-31 Numab AG Bispecific constructs and their use in the treatment of various diseases
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010136172A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2015013671A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015150447A1 (en) * 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Multispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIMOTHY J. EGAN ET AL: MABS, vol. 9, no. 1, 27 October 2016 (2016-10-27), US, pages 68 - 84, XP055467772, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1248012 *

Also Published As

Publication number Publication date
CN116199785A (zh) 2023-06-02
KR102763369B1 (ko) 2025-02-05
CN116041530A (zh) 2023-05-02
JP7399852B2 (ja) 2023-12-18
CN110831973A (zh) 2020-02-21
AU2025204860A1 (en) 2025-07-17
NZ760913A (en) 2024-10-25
WO2019005639A2 (en) 2019-01-03
JP2020530777A (ja) 2020-10-29
KR20250024104A (ko) 2025-02-18
IL271257B1 (en) 2024-07-01
IL313468A (en) 2024-08-01
EP3645049A4 (en) 2021-06-30
US20220002406A1 (en) 2022-01-06
KR20200092301A (ko) 2020-08-03
US11787863B2 (en) 2023-10-17
CN110831973B (zh) 2023-08-15
EP3645049A2 (en) 2020-05-06
CN116948035A (zh) 2023-10-27
IL271257A (en) 2020-01-30
AU2018295118A1 (en) 2020-02-06
IL271257B2 (en) 2024-11-01
WO2019005639A3 (en) 2019-02-07
CA3068045A1 (en) 2019-01-03
RU2020102662A (ru) 2021-07-27
SG11201912864SA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2018295118B2 (en) Multi-specific antibodies and methods of making and using thereof
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
KR102837521B1 (ko) Bcma에 결합하는 항체 및 이의 용도
AU2018250301B2 (en) Anti-ICOS agonist antibodies and uses thereof
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN107922496B (zh) IL2Rβ/通用γ链抗体
KR20220033522A (ko) 항-cd73 항체와의 조합 요법
KR20180082563A (ko) 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
KR20170091179A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
KR102558418B1 (ko) Pd-1에 결합하는 항체 및 그 용도
CN110869392A (zh) 用抗gitr激动性抗体治疗癌症
KR20160072268A (ko) 항-efna4 항체-약물 접합체
TW202313110A (zh) 癌症之治療
WO2020214957A1 (en) Anti-pd-1 antibodies and uses thereof
RU2837770C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
HK40018991B (zh) 多特异性抗体及其制备和使用方法
RU2839071C1 (ru) Антитела, связывающие siglec15, и варианты их применения
CN115667297B (zh) 结合il6r的抗体及其用途
HK40019010B (zh) 多特异性抗体及其制备和使用方法
CN117460529A (zh) 抗icos抗体的用途
HK40033442B (zh) 结合pd-1的抗体及其用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER APPLICANT(S): SICHUAN BAILI PHARMACEUTICAL CO. LTD.; SYSTIMMUNE, INC.

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): SICHUAN BAILI PHARMACEUTICAL CO. LTD.; SYSTIMMUNE, INC.

PC1 Assignment before grant (sect. 113)

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER APPLICANT(S): BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.; SYSTIMMUNE, INC.

FGA Letters patent sealed or granted (standard patent)